Liver cancer combo trial halted early: what we know
NCT ID NCT04050462
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 25 times
Summary
This study tested whether adding either BMS-986253 or cabiralizumab to the immunotherapy drug nivolumab could shrink tumors better than nivolumab alone in people with advanced liver cancer. Only 13 patients enrolled before the trial was stopped early. The goal was to see how many patients had their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
NYU Langone Health
New York, New York, 10016, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.